Eli Lilly and Incyte's eczema treatment delayed at FDA – again

The two pharmaceutical companies have been forced to announce that the FDA's processing of Olumiant as a treatment for atopic dermatitis has been delayed for a second time. This is due to questions surrounding the drug class.
Photo: Mike Blake/REUTERS / X00030
Photo: Mike Blake/REUTERS / X00030
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT

The US Food and Drug Administration, FDA, has again postponed its deadline for responding to Eli Lilly's application for the authorization of Olumiant, which is an eczema treatment for adults.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading